Woost P G, Brightwell J, Eiferman R A, Schultz G S
Exp Eye Res. 1985 Jan;40(1):47-60. doi: 10.1016/0014-4835(85)90107-1.
Treatment of rabbit corneal wounds with topical corticosteroid retards both epithelial regeneration and healing of penetrating stromal wounds. Currently, no clinical agent is available which accelerates the rate of stromal wound healing. Epidermal growth factor (EGF, 0.5 mg ml-1), fibroblast growth factor (FGF, 20 micrograms ml-1), and insulin (0.5 mg ml-1) were tested for their ability to accelerate healing of totally penetrating wounds in rabbit corneas when the hormones were administered alone or in combination with dexamethasone (1 mg ml-1). After 5 days of treatment with eye drops, the tensile strengths of corneal wounds treated with EGF (54 +/- 4 g mm-1) or treated with EGF and dexamethasone (32 +/- 9 g mm-1) were significantly higher than the tensile strengths of corneal wounds treated with only saline vehicle (3 +/- 1 g mm-1) or dexamethasone (1 +/ 0 g mm-1) (P less than 0.001). The combination of dexamethasone with EGF significantly (P less than 0.025) reduced the strength of corneal wounds compared to treatment with EGF alone. Similarly, the tensile strength of corneal wounds after 5 days of insulin treatment alone (28 +/- 8 g mm-1) or in combination with dexamethasone (25 +/- 7 g mm-1) was significantly increased compared with saline- or dexamethasone-treated corneas (P less than 0.001). In the absence of dexamethasone, EGF increased the tensile strength of corneal wounds significantly better than insulin (P less than 0.01). However, when EGF or insulin were given in combination with dexamethasone there was no significant difference between the tensile strength produced by the peptide hormones. In comparison to the tensile strength of corneal wounds treated by EGF or insulin, treatment with FGF alone (5 +/- 4 g mm-1) or in combination with dexamethasone (2 +/- 1 g mm-1) produced poor wound healing. The in vitro actions of EGF or FGF alone or in combination with dexamethasone were tested for ability to stimulate [3H]-thymidine incorporation into pure cultures of human corneal fibroblasts (HCF) in defined culture medium. EGF (5 mM) or FGF (100 ng ml-1) alone stimulated [3H]-thymidine incorporation approximately 2.5-fold compared to control cultures, whereas in combination with dexamethasone (10 nM), the stimulatory action of FGF, but not EGF, was abolished. Dose-response curves indicated that HCF in culture were very sensitive to EGF, insulin, and FGF with maximum stimulation of [3H]-thymidine incorporation occurring at approximately 1 nM for EGF and insulin and at 100 micrograms ml-1 for FGF. Binding of 125I-EGF to HCF reached maximum after 2 hr at 37 degrees C and was specific, saturable, and of high affinity (half saturation at 1 nM). (ABSTRACT TRUNCATED AT 400 WORDS)
用局部皮质类固醇治疗兔角膜伤口会延缓上皮再生和穿透性基质伤口的愈合。目前,尚无临床可用药物能加快基质伤口的愈合速度。当单独使用或与地塞米松(1毫克/毫升)联合使用时,检测了表皮生长因子(EGF,0.5毫克/毫升)、成纤维细胞生长因子(FGF,20微克/毫升)和胰岛素(0.5毫克/毫升)促进兔角膜完全穿透性伤口愈合的能力。用眼药水治疗5天后,用EGF治疗的角膜伤口(54±4克/毫米-1)或用EGF和地塞米松治疗的角膜伤口(32±9克/毫米-1)的抗张强度显著高于仅用生理盐水载体治疗的角膜伤口(3±1克/毫米-1)或地塞米松治疗的角膜伤口(1±0克/毫米-1)(P<0.001)。与单独用EGF治疗相比,地塞米松与EGF联合使用显著(P<0.025)降低了角膜伤口的强度。同样,单独用胰岛素治疗5天后(28±8克/毫米-1)或与地塞米松联合使用(25±7克/毫米-1)的角膜伤口的抗张强度与用生理盐水或地塞米松治疗的角膜相比显著增加(P<0.001)。在没有地塞米松的情况下,EGF比胰岛素显著更好地增加了角膜伤口的抗张强度(P<0.01)。然而,当EGF或胰岛素与地塞米松联合使用时,肽类激素产生的抗张强度之间没有显著差异。与用EGF或胰岛素治疗的角膜伤口的抗张强度相比,单独用FGF治疗(5±4克/毫米-1)或与地塞米松联合使用(2±1克/毫米-1)产生的伤口愈合较差。单独或与地塞米松联合使用的EGF或FGF的体外作用,在限定培养基中检测刺激[3H] - 胸腺嘧啶核苷掺入人角膜成纤维细胞(HCF)纯培养物的能力。与对照培养物相比,单独的EGF(5毫摩尔)或FGF(100纳克/毫升)刺激[3H] - 胸腺嘧啶核苷掺入约2.5倍,而与地塞米松(10纳摩尔)联合使用时,FGF的刺激作用被消除,但EGF未被消除。剂量反应曲线表明,培养中的HCF对EGF、胰岛素和FGF非常敏感,对于EGF和胰岛素,[3H] - 胸腺嘧啶核苷掺入的最大刺激发生在约1纳摩尔,对于FGF发生在100微克/毫升。125I - EGF与HCF的结合在37℃下2小时后达到最大值,且具有特异性、可饱和性和高亲和力(1纳摩尔时半饱和)。(摘要截断于400字)